Tirzepatide vs Retatrutide
An approved dual agonist versus an investigational triple agonist — compared on mechanism, trial maturity, weight-loss numbers, and the gap between a phase-2 signal and an approved drug.
Tirzepatide is FDA-approved with a large phase-3 evidence base; retatrutide is investigational, and its bigger headline weight-loss figure comes from a single phase-2 trial in a drug that is not approved and has no cardiovascular-outcomes data. For anyone choosing today, tirzepatide is the real option — retatrutide is a promising candidate still being tested, and anything sold under its name outside a trial is an unapproved research chemical.
| Tirzepatide | Retatrutide | |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | Triple GIP + GLP-1 + glucagon receptor agonist |
| Regulatory status | FDA-approved (Mounjaro, Zepbound) | Investigational — not approved for any indication (phase 3 TRIUMPH program) |
| Best evidence (weight loss) | Grade A — up to ~21% mean loss at 72 wks on 15 mg (SURMOUNT-1) | Grade C — up to ~24% at 48 wks on 12 mg, from a single phase 2 trial |
| Human trial evidence | Large randomized phase 3 program (SURPASS, SURMOUNT) | One phase 2 obesity trial; confirmatory phase 3 still reporting |
| Cardiovascular evidence | Grade C — dedicated outcomes trial (SURPASS-CVOT) ongoing | Grade U — no cardiovascular-outcomes data exist |
| Common side effects / safety | Nausea, diarrhea, vomiting, constipation; rodent-based thyroid C-cell boxed warning | Nausea, diarrhea, vomiting; dose-dependent heart-rate increase; no approved safety label |
| Half-life / dosing | ~5 days; weekly subcutaneous injection | ~6 days; weekly subcutaneous injection |
| Product quality | Approved pharmaceutical supply chain | Anything sold as 'retatrutide' outside a trial is an unregulated research chemical of unknown identity and dose |
How to read this comparison
These two are often set side by side because retatrutide’s phase-2 numbers are the only ones that have out-run tirzepatide’s. But they sit at completely different stages of evidence, and that difference matters more than the headline percentages.
Tirzepatide is a finished, approved medicine. Its dual-agonist weight-loss and glycemic effects are Grade A, established across the large, randomized SURPASS and SURMOUNT programs. Its cardiovascular benefit is still Grade C — plausible and directionally supported, but the dedicated SURPASS-CVOT outcomes trial has not yet reported.
Retatrutide is an investigational drug. Adding glucagon-receptor activity to the GIP/GLP-1 combination produced a striking result — up to roughly 24% mean weight loss at 48 weeks on the highest dose — but that comes from a single phase 2 trial. We grade its weight-loss outcome C (Preliminary), not A, precisely because it has not cleared the bar an approved drug has: the confirmatory phase 3 TRIUMPH program is still reporting, and there is no cardiovascular-outcomes data at all.
The honest read is not “retatrutide beats tirzepatide.” It is that a bigger number from one early trial is not the same kind of evidence as a proven, approved drug. Retatrutide may well live up to its promise — but until phase 3 confirms it and a regulator approves it, the comparison is between something real and something still being tested. And material sold as retatrutide outside a clinical trial is an unapproved research chemical, not the drug Lilly is studying.
Neither of these is a decision you make from a web page. Tirzepatide is a prescription medication; retatrutide, for now, is only legitimately available inside a supervised trial. Which fits — if either does — is a conversation with a clinician.
A note on "dose"
Any doses shown here are the amounts studied in trialsor the approved label schedule — not a recommendation, and not the same thing as a dose someone reports using online. See how we separate dose language.
References